Myelodysplastic Syndromes

Latest News
April 11th 2025

Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS: Caspian Oliai, MD, MS

March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

March 26th 2025

ELN Scoring System Shows Similar Accuracy to iFS for MDS Diagnosis

March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

March 14th 2025

Neutrophil Subset Changes Give Insight Into First Mechanisms of MDS, AML

Video Interviews
View All
April 2nd 2025

Orca-T Shows Efficacy, Reduced GVHD Risk in Acute Leukemia, MDS: Caspian Oliai, MD

February 7th 2025

Treosulfan Approval Offers Novel Option for Allo-HSCT Conditioning in AML/MDS

February 6th 2025

Treosulfan Shown Effective, Safe as Conditioning for Allo-HSCT in AML/MDS

March 17th 2024

Dr Jennifer Vaughn: We Can Provide Aggressive, Effective Treatment, but Help Patients Maintain Quality of Life

February 3rd 2023

Treatment Patterns in the Management of MDS

January 27th 2023

Treatment Paradigm in Lower-Risk MDS (LR-MDS) Patients

January 20th 2023

TP53 Mutation and Its Impact on Patient Outcomes in MDS

December 29th 2022

Age Considerations for Findings on Venetoclax Combined With CLIA for AML, High-Risk MDS

December 23rd 2022

Dr Patrick Reville: How Patients With MDS, MPAL Responded to Venetoclax With CLIA

December 21st 2022

ASCERTAIN Trial Overview

More News

A 1-year interim analysis of the ACROBAT study found AlloHeme accurate and sensitive for monitoring relapse after allo-HSCT in AML and MDS. | Image credit: Елена Бутусова - stock.adobe.com
February 21st 2025

NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS

Rose McNulty
The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
FDA Approval | Image credit: wladimir1804 - stock.adobe.com
February 19th 2025

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths

Rose McNulty
The FDA approved Amneal Pharmaceuticals' generic lenalidomide capsules, referencing Celgene's Revlimid, in multiple strengths.
MDS blood test | Image credit: MdBabul - stock.adobe.com
January 29th 2025

Characterizing Patients With MDS Who Undergo Allo-HSCT

Karen Jacobson-Sive
Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.
FDA approved. | Image Credit: Pawel - stock.adobe.com
January 23rd 2025

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

Rose McNulty
The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Two abstracts presented at ASH 2024 provided insight into MDS response to hypomethylating agents (HMAs) | Image credit: Sviatlana - stock.adobe.com
January 19th 2025

Exploring Response to HMAs for MDS Across Various Patient Types

AJMC Contributor
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs).
First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
January 18th 2025

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

Rose McNulty
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
MDS blood test | Image credit: MdBabul - stock.adobe.com
January 13th 2025

Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS

AJMC Contributor
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Nicole Gieselhuber, MD, PhD | Image credit: Ohio State University
January 2nd 2025

Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study

Mary Caffrey Nicole Grieselhuber, MD, PhD
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Top 5 MDS articles of 2024
December 30th 2024

Top 5 Most-Read MDS Content of 2024

Christina Mattina
This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors for progression, and more.
MDS graphic | Image Credit: © Sviatlana-stock.adobe.com
December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD
Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
MDS | Image Credit: © ibreakstock-stock.adobe.com
December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive
Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.
Visualization of myelodysplastic syndromes | image credit: Lily - stock.adobe.com
December 11th 2024

Additional Hematopoietic Malignancy Predispositions Accounted for in Updated Surveillance Recommendations

AJMC Contributor
The recommendations for surveillance account for newly identified hematopoietic malignancy predispositions (HMP) and HMP genes, as well as a greater understanding of the prevalence of germline variants putting children as an increased risk of MDS and other HMs.
Child in hospital looking out window | Image credit: MIA Studio - stock.adobe.com
November 29th 2024

Survivors of Childhood Cancer at 9-Fold Greater Risk for Late Subsequent Leukemia 

Karen Jacobson-Sive
High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of developing late subsequent leukemia.
MDS wooden blocks held by hand in glove | Image Credit: © Sviatlana - stock.adobe.com
November 27th 2024

Venetoclax May Be an Option for Children With R/R AML, MDS

Jared Kaltwasser
The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Pediatrician test results tablet parent child | Image Credit: © nimito - stock.adobe.com
November 11th 2024

Increased Surveillance Recommended for Children at Risk for Hematopoietic Malignancy Predisposition

Karen Jacobson-Sive
Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, according to researchers.
stem cells | Image Credit: © jarun011 -stock.adobe.com
November 8th 2024

Study Explores Radiation-Free Transplant Approach for Patients With Dyskeratosis Congenita

Kimberly Rath, PharmD
A new study finds that eliminating radiation from conditioning regimens in patients with dyskeratosis congenita undergoing allogeneic hematopoietic cell transplantation did not negatively affect survival or increase complications.
Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
November 2nd 2024

Patients With MDS Disagree With Physicians About Symptom Frequency

Jared Kaltwasser
Physicians also differed from caregivers when asked how many hours of caregiving patients required each week.
Myeloid malignancy concept, blood cells floating | image credit: Eleni - stock.adobe.com
October 18th 2024

Phase 1b/2 Study Supports Use of Telaglenastat and Azacytidine in Advanced MDS

Kimberly Rath, PharmD
A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic syndromes (MDS), with promising results.
Cancer cells | Image credit: Sodapeaw - stock.adobe.com
October 11th 2024

In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

Jared Kaltwasser
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).
Doctor consulting with patient | Image credit: ARMMY PICCA - stock.adobe.com
October 4th 2024

JAK Inhibitors Show Promise in Concurrent Myeloid Disorders, IADs

AJMC Contributor
In recent years, it’s been estimated that 10% to 28% of patients with myeloid disorders develop adult onset inflammatory and autoimmune disorders (IADs), complicating treatment.
Hemoglobin is responsible for transporting oxygen throughout the body, which is imperative for a multitude of functions | image credit: Justlight - stock.adobe.com
September 21st 2024

Low Hemoglobin, IDH2 Mutation Indicative of Poor Survival in MDS

Nameera Temkar, MD
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.
Celiac disease and the body | Image Credit: reineg-stock.adobe.com
September 13th 2024

Celiac Disease Associated With Varying Risks for Cancers

Karen Jacobson-Sive
Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin cancers, but presents a lower risk for respiratory malignancies.
Telomeres act as protective caps on the ends of chromosomes | image credit: Anastasiia - stock.adobe.com
September 3rd 2024

RIOK2 Regulates Telomerase Subunits to Prevent Telomere Shortening

Gwen Mergian
New research linking telomere shortening to myelodysplastic syndromes (MDS) offers substantial therapeutic implications for affected patients and MDS research.
Patient takes medicine | Image Credit: © Seventyfour - stock.adobe.com
August 25th 2024

High Patient Satisfaction Seen With Oral DEC-C in Myelodysplastic Syndromes

Kimberly Rath, PharmD
Patients with myelodysplastic syndromes report high satisfaction with oral decitabine/cedazuridine (DEC-C) vs traditional intravenous or subcutaneous hypomethylating agents.
red blood cells | Image Credit: kolonko-stock.adobe.com
August 23rd 2024

Clinical, Economic Outcomes Associated With Alloimmunization in MDS

AJMC Contributor
The researchers found inferior outcomes and higher accrued costs associated with alloimmunization in patients with myelodysplastic syndromes (MDS), a disease that relies on transfusion of red blood cells.
Guidelines folder | Image Credit: tashatuvango-stock.adobe.com
August 16th 2024

New Guidelines Clarify MDS Classification, Highlight Diagnostic Nuances

Gayle Turim Dickstein
Authors acknowledge that both the 2022 World Health Organization and International Consensus Classification myelodysplastic syndrome criteria sets have value, while sorting out their similarities and differences.
science and teamwork | Image Credit: Coetzee peopleimages-stock.adobe.com
August 9th 2024

Lab Technology Advances Detection of MDS

Gayle Turim Dickstein
More and more hematology factors and parameters can be analyzed with advanced equipment to better pinpoint which patients might have myelodysplastic syndromes (MDS)—but the differences in leading makers’ systems can be tricky to maneuver.
MDS wooden blocks | Image Credit: Sviatlana - stock.adobe.com
August 2nd 2024

Report: ESAs Largely Ineffective in Lower-Risk MDS

Jared Kaltwasser
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).
stem cell transplant | Image Credit: Vadim-stock.adobe.com.jpeg
July 28th 2024

HCT Outcomes Show Improvement With Posttransplant Cyclophosphamide

Karen Jacobson-Sive
Post–hematopoietic cell transplantation (HCT) prophylaxis using cyclophosphamide to stave off graft-vs-host disease had positive results compared with calcineurin inhibitor–based prophylaxis, regardless of whether the patient had a matched or unmatched donor.
12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo